Drug Trial Radar · NCT02727751
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
Last checked: Nov 19, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
Mar 2016
Primary completion
Oct 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.
Conditions
- Constipation Predominant Irritable Bowel Syndrome
Interventions
TenapanorDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events in >2% PatientsTime frame: 52-55 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ardelyx Clinical Site
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.